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Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma
associated herpesvirus (KSHV), is associated with the aetiopatho-
genesis of Kaposi’s sarcoma (KS), body cavity B-cell lymphoma,
also called primary effusion lymphoma (PEL), and multicentric
Castleman’s disease (MCD) (Chang et al, 1994; Chang and
Moore, 1996; Ganem, 1996; IARC, 1997; Boshoff and Weiss,
1998; Schulz, 1998). Current serological and molecular assays
indicate that HHV-8 infection is not widespread, but predomi-
nantly restricted to populations at risk of AIDS-associated,
endemic, or classic KS (Chang and Moore, 1996; IARC, 1997;
Boshoff and Weiss, 1998; Schulz, 1998). The assays employed to
measure HHV-8 antibodies include immunofluorescence assays
(IFA) for latent and lytic proteins (Gao et al, 1996a; Kedes et al,
1996; Miller et al, 1996); ELISA for latent associated nuclear
antigen (LANA) (Oskenhendler et al, 1998; Gao et al, 1996b),
ORF 65 (Simpson et al, 1996), ORF 26 (Davis et al, 1997), and
whole virus (Chatlynne et al, 1998); as well as K8.1 (Raab et al,
1998), capsid protein (Lin et al, 1997), and BC-1 cell extract
(Schulz, 1998) immunoblots.
There are no serological data available on the prevalence of
HHV-8 in Southeast Asia or the Indian subcontinent. Although
HIV is now a common problem in this subcontinent (Bhoopat
et al, 1994), classic and endemic KS do not occur (Wabinga et al,
1993; Ziegler, 1993; Bhoopat et al, 1994; Sukpanichant et al,
1998), and the incidence of AIDS-associated KS appears very low
(Bhoopat et al, 1994; Sukpanichant et al, 1998). We investigated
the prevalence in healthy individuals of HHV-8 (Table 1) in
Southeast Asia (n = 234 from Malaysia and Thailand), Indian
subcontinent (n = 188 from India and Sri Lanka), the West Indies
(n = 410 from Jamaica and Trinidad), and three African countries
(n = 164 from Uganda, Zambia and Ghana) and compared this
with healthy donors’ sera from the USA (n = 135). Where avail-
able, we also tested a limited number of sera from HIV-1-infected
patients (Table 2) for HHV-8 antibody to see if the prevalence
differed from the healthy population: India (n = 42), Thailand
(n = 196), Zambia (n = 25), Uganda (n = 35), Trinidad (n = 12) and
the USA (n = 124).
MATERIALS AND METHODS
We employed a recently described whole virus enzyme-linked
immunosorbent assay (ELISA; Advanced Biotechnologies Inc,
Columbia, MD, USA) using sucrose-banded HHV-8 virus lysate
as the source of antigen (Chatlynne et al, 1998). A whole virus
ELISA has advantages over using individual viral proteins as a
source of antigen, since the viral lysate contains a broad spectrum
of seroreactivity compared to that detected by a single viral protein
in ELISA, IFA, or immunoblots. Since this ELISA detects
predominantly proteins to lytic antigens, we also compared this
ELISA to a lytic antigen IFA in a subset of KS- and HIV-positive
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Summary Seroprevalence of HHV-8 has been studied in Malaysia, India, Sri Lanka, Thailand, Trinidad, Jamaica and the USA, in both healthy
individuals and those infected with HIV. Seroprevalence was found to be low in these countries in both the healthy and the HIV-infected
populations. This correlates with the fact that hardly any AIDS-related Kaposi’s sarcoma has been reported in these countries. In contrast, the
African countries of Ghana, Uganda and Zambia showed high seroprevalences in both healthy and HIV-infected populations. This suggests
that human herpes virus-8 (HHV-8) may be either a recently introduced virus or one that has extremely low infectivity. Nasopharyngeal and oral
carcinoma patients from Malaysia, Hong Kong and Sri Lanka who have very high EBV titres show that only 3/82 (3.7%) have antibody to HHV-
8, demonstrating that there is little, if any, cross-reactivity between antibodies to these two gamma viruses. © 1999 Cancer Research Campaign
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Correspondence to: DV Ablashipatient sera (n = 58). For the ELISA, sera were diluted at least 1:80
and for lytic IFA, sera were tested at a dilution of 1:40. Frozen and
coded sera were shipped to the laboratory in Columbia, Maryland,
for testing. Serum (obtained from Malaysia, Hong Kong and Sri
Lanka) from patients with nasopharyngeal carcinoma, oral carci-
noma and other diseases (infectious mononucleosis and African
Burkitt’s lymphoma) were also titred for Epstein–Barr virus
(EBV) to see if patients with high EBV titres also tested positive
for HHV-8, and to see if antibodies to EBV might cross-react with
HHV-8 (Table 3).
Collection of serological samples
Serum/plasma samples from the USA
The healthy subjects consisted of blood donors and laboratory
workers. The samples were obtained from a blood bank and drawn
in a clinical laboratory. The HIV+, classical KS, and HIV+ KS
sera came from the Department of Dermatology, New York
University Medical Center, North Shore University Hospital
(kindly provided by Drs A Friedman-Kien and Mark Kaplan), and
the Norris Cancer Research Center, University of Southern
California, Los Angeles (collected by Dr P Gill).
Samples from India
These were collected from individuals at blood bank facilities in
Bombay, Madras and New Delhi for HIV testing. Therefore, the
samples consisted of both healthy donors (HIV-negative) and HIV-
positive individuals who were antibody-positive by radioimmuno-
assay and Western blot.
Samples from nasopharyngeal carcinoma, oral carcinoma,
infectious mononucleosis, African Burkitt’s lymphoma and
from healthy donors and HIV+ patients from Africa
Most of the nasopharyngeal carcinoma (NPC) and all of the oral
carcinoma (OC) sera were provided by the University of Malaya,
Kuala Lumpur. All of the OC sera originally came from Sri Lanka
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Table 1 Detection of IgG antibody to HHV-8 (KSHV) lytic proteins by ELISA of populations from the USA, India, Sri Lanka, Thailand, Malaysia, Jamaica,
Trinidad, Uganda, Zambia and Ghana
Age (years) Number of antibody
Country range Male–Female Group positive/number testeda Per cent positive
Infected controls 54–92 19–1 A. Classical (HIV-negative) 20/20 100.0
(Kaposi’s sarcoma) 33–61 10–0 B. HIV-infected 9/10 90.0
1. USA 22–78 87–48 Blood donors 7/135 5.2
2. Southeast Asia
Indiab 20–58 56–52 Healthy individuals 4/108 4.0
Thailandc 17–69 39–36 Healthy individuals 3/75 4.0
Malaysia 9–85 113–46 Healthy individuals 7/159 4.4
Sri Lankab 21–78 48–32 Healthy individuals 3/80 3.8
3. Caribbean
Jamaica 18–64 124–123 Blood donors 9/250 3.6
Trinidadd 20–>50 89–67 Blood donors 2/160 1.3
4. Africa
Uganda 18–67 44–18 Healthy individuals 24/62 38.7
Zambia 17–68 22–18 Healthy individuals 15/40 37.5
Ghana 13–72 47–15 Healthy individuals 26/62 41.9
aAll sera were tested for IgG at a dilution of 1:80 or 1:100 using sucrose density gradient purified HHV-8 as source of antigen. Negative: OD ≤ 0.113, equivocal:
OD > 0.113 and < 0.128, positive: OD ³ 0.128. HHV-8 antibody positive sera were rerun for conformation by IFA for lytic antigens at dilutions of 1:40. A few
antibody negative sera from each country were run as controls. bSera were collected in order to screen for HHV-6 and EBV. cSera were collected to screen for
HIV. Age and sex of three individuals were not traceable. dFour individuals’ age and sex data were not available.
Table 2 Distribution of HHV-8 IgG antibody in HIV-1-positive individuals who do not have Kaposi’s sarcomaa
Age (years) No. of antibody Per cent
Country Group range Male–Female positive/No. tested Positive
USA HIV + homosexual men 21–55 62–0 27/62 43.5
HIV + Non-KS (current)b 33–52 16–0 8/16 50.0
HIV + Non-KS (retrospective)c 31–58 46–0 13/46 28.3
India HIV-1 + 20–58 30–12 1/42 2.4
No HIV-associated KS reported
Thailand HIV-1+ 19–41 100–96 22/196 11.2
No HIV-associated KS reported
Uganda HIV-1+ 20–62 22–13 16/35 45.7
Zambia HIV-1+ 22–69 18–7 11/25 44.0
Trinidad HIV-1+ 20–50 9–3 0/12 0
aSera were tested by ELISA to purified virus, some LNA (BCP-1 cell antibody), and by IFA to lytic proteins (KS-1 cell substrate). bSix of the eight that were
antibody positive have since developed KS. cPatients either died or did not develop KS in the 10 years following the sample.to the University of Malaya for HHV-6/HHV-7 and other studies.
The other NPC, African Burkitt’s lymphoma (BL), and infectious
mononucleosis (IM) sera were obtained from the Department of
Microbiology/Immunology, Georgetown University School of
Medicine, Washington, DC. These NPC sera originally came from
Hong Kong (kindly supplied by Dr Ng). The BL sera (Table 3)
from Ghana were originally part of another study on EBV
conducted by Drs Robert Bigger and Paul Levine (National Cancer
Institute’s (NCI) Burkitt’s lymphoma project). These sera were
collected in the late 1960s and stored at the NCI Natural Products
Repository. Some of the African sera (Uganda and Zambia) were
made available by the Georgetown University, Washington, DC,
the Cancer Research Institute, London, UK and the Natural
Products Repository, National Cancer Institute, Frederick Cancer
Research and Development Center, Frederick, Maryland. All of
the healthy donors’ sera from Ghana were also obtained from the
Natural Products Repository of NCI and were collected in 1990
and 1991 from the Roforidua region for other NCI studies (ID =
Ghana/Africa, ID = ward controls and ID = Kocle hospital).
Serum samples from Malaysia
These were collected from healthy donors by two of the authors,
Drs Yadav and Norhanom, at the Institute of Advanced Studies,
University of Malaya, as a part of an EBV seroepidemiology
study. These sera were obtained from Chinese, Malays and
Indians, whereas the NPC sera were from Chinese and Malays.
These sera were stored at the University facility at –20°C.
Serum samples from Thailand
Serum samples of HIV-negative donors were collected at the
Mahidol University of Thailand. The serum samples from HIV-
positive donors were collected from the Remune Trail Center.
Among the healthy donors (HIV-negative), three were found to be
HHV-8 antibody-positive workers who applied for a permit to seek
work in the Middle East. The age and sex of four serum samples
were not traceable (Table 1).
Serum samples from Jamaica
Sera samples from normal blood donors were obtained from the
National Transfusion Service, Kingston, Jamaica.
Serum samples from Trinidad
All samples from Trinidad were collected (Drs Cleghorn, Jack and
Edwards) after informed consent from adult STD clinic attendees
as part of a larger NIH-funded study to screen for early HIV-1
infection in the period 1995–1997.
Age and sex of donors
Age and sex of individuals from whom sera were collected varied
in each group, whether collected at a clinic (as previously indi-
cated), blood bank, or as part of a study group from healthy adults
in the USA, India, Sri Lanka, Malaysia, Thailand, Uganda,
Zambia, Ghana, Jamaica and Trinidad, and HIV-infected individ-
uals from the USA, India, Trinidad, Thailand, Uganda, Zambia
and Ghana (with and without KS). The age (range) and sex
distribution of all sera tested are provided in Table 1, 2 and 3.
RESULTS AND DISCUSSION
Table 1 shows the distribution of HHV-8 IgG antibodies in healthy
individuals from the countries tested. We used sera from patients
with KS for a positive control, and all of these sera were positive
for HHV-8 IgG antibody. The prevalence of HHV-8 in 5.2% of
blood donors in the USA correlates with that previously reported
using both latent IFA and immunoblot assays (Gao et al, 1996a;
Kedes et al, 1996; Miller et al, 1996). The higher prevalence of
HHV-8 in adults from Uganda (38.7%) and Zambia (37.5%) corre-
lates with the incidence of endemic KS and the high incidence of
AIDS-associated KS in these countries (Wabinga et al, 1993). In
Ghana, however, the high seroprevalence of HHV-8 (41.9%) does
not correlate with an increased incidence of African endemic KS
(Ziegler, 1993), indicating that co-factors are probably necessary
to precipitate endemic KS (Ziegler, 1993; Bourboulia et al, 1998).
The high seroprevalence of HHV-8 antibody to lytic viral antigens
further supports another study of pregnant African women and
prostitutes from Cameroon (Bestetti et al, 1998) in which 52.6%
who were HIV-positive demonstrated IgG antibody to HHV-8,
compared to 42.6% who were HIV-negative. This is the first report
to document the prevalence of KSHV in the Far East in healthy
individuals (Table 1) and in HIV-1-positive individuals from these
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Table 3 Sera with high EBV antibody titres have no cross-reactivity with HHV-8
EBV IgG (titre) of
Age (years) Range of EBV-VCA Range of EBV-EA HHV-8 antibody HHV-8 IgG antibody
Sera type No. tested Male–Female range antibody titresa antibody titresb positive samples (titre)
Nasopharyngeal
carcinoma patients (%)
(Malaysia and IgG IgA 1:1280 2/42 1:80
Hong Kong) 42 32–10 35–78 1:640–>1:5120 1:80–>1:320 1:2560 (4.8) 1:160
Oral squamous
carcinoma patients IgG 1/40 ³1:80
(Sri Lanka) 40 30–10 21–82 1:640–³1:1280 NDc 1:640 (2.5)
Infectious
mononucleosis patients IgM 0/7
(USA) 7 5–2 17–25 1:40–³1:160 ND – (0)
Burkitt’s lymphoma
children IgG IgG 1/12 (1:160)
(Ghana) 12 8–4 6–16 1:320–³1:1280 1:80–1:320 1:640 (8.3)
aThe sera for antibody to EBV-VCA were tested by IFA using P3HR-1 Clone 1B cells of which 20% expressed VCA. bThe antibody to EBV-EA was tested by IFA
on Raji cells superinfected with EBV isolated from P3HR-1 cells. At 48 hours post infection, >50% of the Raji cells expressed EA. cND – not donecountries (Table 2). As in other countries where endemic and
classic KS are rare (e.g. Northern America and North Western
Europe), HHV-8 infection appears restricted to less than 5% of
healthy adults. Similarly, HHV-8 is not a common infection of
healthy adults in the two West Indian countries tested: Trinidad
(1.3%) and Jamaica (3.6%) (Manns et al, 1998). In HIV-1-infected
populations, seroprevalence of HHV-8 is generally elevated above
that of the general population in areas where KS is associated with
HIV infection (e.g. USA); but in areas (India, Thailand) where
HIV infection is on the increase, the lack of evidence of KS does
not correlate. In spite of the high prevalency of HIV and AIDS in
India and Thailand, the seroprevalency of HHV-8 is much lower in
this population than in comparable HIV-positive populations in the
USA or Africa (Table 2). The number of HIV-positive samples
from Trinidad is too small to draw any conclusions; however, it
may be similar to India and Thailand.
Since infection with EBV is widespread in the Far East and
Indian subcontinent and is associated with NPC and endemic
Burkitt’s lymphoma, we tested sera from 40 patients with NPC
from Malaysia and Hong Kong, from 40 patients with oral squa-
mous carcinoma (OC) from Sri Lanka, from seven IM patients in
the USA, and from 12 children with BL from Ghana to determine
whether there is any immunologic cross-reactivity between the
two human gamma herpesviruses, i.e. EBV and HHV-8, using this
ELISA (Table 3). EBV antibodies were tested by IFA for anti-
VCA IgG using a preparation of P3HR-1 cells (Clone 1B), that is
about 20% positive for EBV viral capsid antigen (VCA). IgG and
IgA antibody to EBV early antigen (EA) was tested by IFA with
Raji cells superinfected with the P3HR-1 strain of EBV. After 48 h
superinfection, approximately 60% of the cells are positive for EA
as determined by monoclonal antibodies to EA-diffuse (EA-D)
and EA-restricted (EA-R) (kindly provided by Dr Gary Pearson of
the Georgetown University School of Medicine, Washington, DC).
To test for EBV IgM, sera were first preabsorbed to remove IgG
antibodies and then incubated on fixed P3HR-1 cells for 3 h.
Table 3 shows the results of this study. The 42 NPC patients had
very high IgG and IgA antibody titres to EBV-VCA and EBV-EA,
but only two of these patients demonstrated antibodies to HHV-8.
In addition, one serum from 40 patients with OC tested positive for
HHV-8 IgG. Out of 12 BL patients with antibody to EBV, one had
antibody to HHV-8. Seven IM sera with EBV IgM antibody were
all negative for HHV-8 IgG. The titres of HHV-8 IgG-positive
sera, i.e. NPC, OC and BL, are given in Table 3, which showed
that the titres were not elevated (as observed in KS sera)
(Chatlynne et al, 1998) in spite of the high EBV titres antibody
(Table 3). This supports a lack of cross-reactivity between HHV-8
and anti-EBV antibodies in this ELISA, and further indicates that
the HHV-8 IgG antibody detected in the general populations, HIV-
positive individuals, and KS patients of the various countries
tested was specific. This data further supports our previous finding
where KS sera, after adsorption for EBV antibody, retained the
HHV-8 IgG (Chatlynne et al, 1998).
In this study, we show that HHV-8 is not a common human
pathogen in Southeast Asia or the Caribbean. Current data indicate
that HHV-8 infection is more prevalent in countries where classic
and endemic KS occurs (Whitby et al, 1998). In these countries,
horizontal transmission and mother-to-child transmission are
likely to occur (Bourboulia et al, 1998; Luppi et al, 1998; Gessain
et al, 1999). In countries with a low incidence of classic or
endemic KS, HHV-8 is predominantly found in homosexual men
at risk of developing KS (Luppi et al, 1998; Martin et al, 1998;
Verbeek et al, 1998), and is a sexually transmitted agent among
these individuals (Martin et al, 1998). In Southeast Asia and the
Caribbean, HHV-8 might be a relatively newly introduced
pathogen. The restricted distribution of HHV-8 in these popula-
tions also correlates with the relatively low incidence of reported
cases of classical KS or AIDS KS (Gill, personal communication,
1998; Jensen, personal communication, 1998). Longitudinal
follow-up studies of individuals infected with HHV-8 in Southeast
Asia and the Caribbean will help to assess the participation of this
viral agent in the pathogenesis of KS and other diseases or malig-
nancies. Future studies will attempt to determine the mode(s) of
transmission of HHV-8 in the Far East and whether HHV-8 was
present in sera collected prior to the AIDS epidemic.
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